Answers are grounded in this paper and cite their sources.
Expanding the label of ETI to rare responsive CFTR variants will make at least 91.5 % of pwCF eligible to this disease-modifying therapy.
No takes yet. Share an insight, caveat, or question.
Burgel et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: